Merck Serono
Merck KGaA Updates Clinical Trial Plans for Several Precision Oncology Candidates
The Darmstadt, Germany-based drugmaker outlined its strategy for advancing an ATR inhibitor, a PARP inhibitor, and an antibody-drug conjugate.
FDA Approves Merck KGaA's Tepmetko for Non-Small Cell Lung Cancer With METex14 Alterations
The drug received accelerated approval for metastatic non-small cell lung cancers with MET exon 14 skipping alterations based on the Phase II VISION trial.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Bavencio Presents Potentially Curative Option for Patients With Rare PD-L1-Expressing Gestational Tumors
In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.